Nature Medicine· @NatureMedicine · X·· 14 小时前评分70
正文 · 机器翻译
在 #ESMO26：一项 2a 期试验中，使用 GDF15 中和抗体 visugromab + nivolumab 治疗免疫检查点抑制剂初治膀胱癌患者，取得了令人鼓舞的应答，且未出现新的安全性信号 @AndreaNecchi dlvr.it/TW32cC
999 浏览 · 4 赞 · 2 转发 · 1 回复
会议摘要
4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上
Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.org帖内回复
- Yusuf Sadek@yusufksadek
@NatureMedicine @AndreaNecchi CPS didn't separate responders here, but baseline CD8+ and CD8+Ki-67+ T cell density on mIF did (p = 0.008 and 0.003 in the visugromab arm). Would a plain H&E TIL score on the baseline TURBT slides pick up the same signal, since every center already has those
来源：Nature Medicine · x.com